Literature DB >> 22251061

Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump.

Per Gisle Djupesland1, Arne Skretting.   

Abstract

BACKGROUND: Delivery of powder formulations to the nose is an attractive alternative for many drugs and vaccines. This study compared the regional nasal deposition and clearance patterns of lactose powder delivered by the OptiNose powder device (Opt-Powder; OptiNose US Inc., Yardley, PA, USA) to that of liquid aerosol administered via a traditional hand-actuated liquid spray pump (Rexam SP270, Rexam Pharma, France).
METHODS: The study was an open-label, crossover design in seven healthy subjects (five females, two males). The regional nasal deposition and clearance patterns of the Opt-Powder device were compared to a traditional liquid spray pump by dynamic gamma camera imaging after administration of either (99m)Tc-labeled lactose powder or liquid (99m)Tc- diethelyne triamine pentaacetic acid-aerosol. The gamma camera images were scaled and aligned with sagittal magnetic resonance images to identify nasal regions. Possible deposition of radiolabeled material in the lungs following both methods of delivery was also evaluated.
RESULTS: Both powder and spray were distributed to all of the nasal regions. The Opt-Powder device, however, achieved significantly larger initial deposition in the upper and middle posterior regions of the nose than spray (upper posterior region; Opt-Powder 18.3% ± 11.5 vs. Spray 2.4% ± 1.8, p<0.02; sum of upper and middle posterior regions; Opt-Powder 53.5% ± 18.5 vs. Spray 15.7% ± 13.8, p<0.02). The summed initial deposition to the lower anterior and posterior regions for spray was three times higher compared to Opt-Powder (Opt-Powder 17.4% ± 24.5 vs. Spray 59.4% ± 18.2, p<0.04). OptiNose powder delivery resulted in more rapid overall nasal clearance. No lung deposition was observed.
CONCLUSIONS: The initial deposition following powder delivery was significantly larger in the ciliated mucosa of the upper and posterior nasal regions, whereas less was deposited in the lower regions. Overall nasal clearance of powder was slower initially, but due to retention in anterior nonciliated regions the overall nasal clearance after spray was slower.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22251061     DOI: 10.1089/jamp.2011.0924

Source DB:  PubMed          Journal:  J Aerosol Med Pulm Drug Deliv        ISSN: 1941-2711            Impact factor:   2.849


  25 in total

Review 1.  The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders.

Authors:  D S Quintana; A J Guastella; L T Westlye; O A Andreassen
Journal:  Mol Psychiatry       Date:  2015-11-10       Impact factor: 15.992

2.  Current understanding of nasal morphology and physiology as a drug delivery target.

Authors:  Julie D Suman
Journal:  Drug Deliv Transl Res       Date:  2013-02       Impact factor: 4.617

Review 3.  Recent progress in mucosal vaccine development: potential and limitations.

Authors:  Nils Lycke
Journal:  Nat Rev Immunol       Date:  2012-07-25       Impact factor: 53.106

4.  Patient-Friendly, Olfactory-Targeted, Stimuli-Responsive Hydrogels for Cerebral Degenerative Disorders Ensured > 400% Brain Targeting Efficiency in Rats.

Authors:  Noha Nafee; Abd El Rahman Ameen; Osama Y Abdallah
Journal:  AAPS PharmSciTech       Date:  2020-11-22       Impact factor: 3.246

5.  Numerical Comparison of Nasal Aerosol Administration Systems for Efficient Nose-to-Brain Drug Delivery.

Authors:  Jingliang Dong; Yidan Shang; Kiao Inthavong; Hak-Kim Chan; Jiyuan Tu
Journal:  Pharm Res       Date:  2017-12-29       Impact factor: 4.200

6.  Deviated nasal septum hinders intranasal sprays: a computer simulation study.

Authors:  D O Frank; J S Kimbell; D Cannon; S S Pawar; J S Rhee
Journal:  Rhinology       Date:  2012-09       Impact factor: 3.681

7.  Exhalation Delivery System: Novel Device for Nasal Polyps Treatment.

Authors:  Rebecca Chu
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2019-09-17       Impact factor: 1.349

8.  Advances in drug development for acute migraine.

Authors:  Ryan J Cady; Candace L Shade; Roger K Cady
Journal:  Drugs       Date:  2012-12-03       Impact factor: 9.546

Review 9.  Intranasal drug delivery for treatment of Alzheimer's disease.

Authors:  Leonor C Fonseca; João A Lopes; João Vieira; Cláudia Viegas; Cláudia S Oliveira; Rafael P Hartmann; Pedro Fonte
Journal:  Drug Deliv Transl Res       Date:  2021-02-26       Impact factor: 4.617

10.  Absorption and Clearance of Pharmaceutical Aerosols in the Human Nose: Development of a CFD Model.

Authors:  Alex Rygg; P Worth Longest
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-01-29       Impact factor: 2.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.